A total of 3 sufferers had a relapse 2 weeks after treatment, and 8 experienced a sustained virologic response 12 weeks after treatment . A total of 3 of 7 patients with a null response to earlier treatment and 5 of 10 with a partial response to earlier treatment had a sustained virologic response 12 weeks following the study treatment. Among patients with IL28B CT and TT genotypes, a sustained virologic response 12 weeks after treatment was achieved in 6 of 12 sufferers and in 2 of 5 , respectively.
In 2009, Alnylam completed a Phase IIa study of ALN-RSV01 in RSV-infected adult lung transplant sufferers. In this small study of 24 patients, ALN-RSV01 was secure and well tolerated, that was the primary study objective. Interpretation of secondary study objectives, including anti-viral activity, was confounded by certain imbalances, for example baseline viral loads, that happened by possibility. By day 14, there is a greater reduction in cumulative symptoms ratings in the ALN-RSV01 group. At the 90 time endpoint, ALN-RSV01 treatment was connected with evidence for improved recovery of lung function and a significant statistically reduction in the incidence of new or progressive BOS. Continue reading “Fred Poordad.”